A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Clinical trial NCT03448042 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03448042
- Sponsor
- Genentech, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-06
- Primary completion
- 2027-11-30
- Enrollment
- 123
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.